Journal
NEOPLASIA
Volume 6, Issue 4, Pages 380-389Publisher
NEOPLASIA PRESS
DOI: 10.1593/neo.04115
Keywords
methylation; breast cancer; tumor suppressor; maspin; laser capture microdissection
Categories
Funding
- NCI NIH HHS [R01 CA075681, R56 CA073612, P01 CA066081, CA66081, CA75681, CA73612, R29 CA073612, CA65562, R01 CA073612] Funding Source: Medline
- NIEHS NIH HHS [P30 ES006694, ES06694] Funding Source: Medline
Ask authors/readers for more resources
The maspin gene functions as a tumor suppressor in human breasts, and its expression is frequently lost during breast cancer progression. In vitro models of human breast cancer indicate that the loss of maspin expression is closely linked to aberrant methylation of the maspin promoter. We conducted a study on 30 archival ductal carcinoma in situ (DICIS) specimens to determine if aberrant methylation of the maspin promoter occurred in vivo, and whether it occurred early in breast cancer evolution. Healthy tissue obtained from reduction mammoplasty was used as normal control. Results from immunohistochemical analysis indicate that maspin expression is lost in a substantial fraction of DCIS specimens (57%). Bisulfite sequencing of DNA isolated from laser capture-microdissected normal and neoplastic ducts showed that loss of maspin expression was often, but not always, linked to aberrant methylation of the maspin promoter, suggesting that other mechanisms, in addition to aberrant methylation, participate and/or cooperate to silence maspin gene expression. Taken together, these results indicate that aberrant methylation of the maspin promoter is an early event in human breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available